RxDoctor Payments DataLook up a doctor →

Kayla Spears, NP

Nurse Practitioner · Michigan City, INNPI 1114693108

Payments from drug & device makers

$10,305in general payments, 2019–2025

Across 654 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$870
  • Recordati_rare_diseases_inc.$784
  • Bayer$603
  • Corcept Therapeutics$567
  • Amgen$506
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$10,305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,305 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$39,669
Medicare patients
206
Services billed
605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$54,633
MounjaroTirzepatide25$43,925
SynjardyEmpagliflozin/Metformin Hcl12$7,459
Lubiprostone11$1,288
Albuterol Sulfate HfaAlbuterol Sulfate44$925
Gabapentin40$716
Fluticasone Propionate71$634
Bupropion XlBupropion Hcl46$606
Morphine Sulfate ErMorphine Sulfate12$499
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$449
Omeprazole32$424
Atorvastatin Calcium67$405
Duloxetine Hcl19$303
Diclofenac Sodium13$302
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav42$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$870$54,63337 claims
Lilly USA, LLCMounjaro$374$43,92525 claims
Boehringer IngelheimSynjardy$346$7,45912 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$24550 claims
Almatica Pharma LLCSertraline Hcl$78$11823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →